Stocks · News reference

Neurocrine Biosciences shares are trading higher after the company announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 in adults with mild to moderate Alzheimer's disease.

Oct 20, 2026, 6:17 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 26, 2026, 1:32 PM
Neurocrine Biosciences Presents New Research on Clinically Meaningful Health Improvements in Tardive Dyskinesia Patients
Neurocrine Biosciences announced new research establishing a 6-point improvement on the EQ Visual Analogue Scale as a benchmark for clinically meaningful change in patients with tardive dyskinesia treated with INGREZZA.
NBIX
Fiscal.aiOct 22, 2026, 10:01 PM
Neurocrine Biosciences Announces Publication of Expert Perspectives on Hyperphagia in Prader-Willi Syndrome
Neurocrine Biosciences announced the publication of expert perspectives in the Orphanet Journal of Rare Diseases regarding the management of hyperphagia in Prader-Willi syndrome.
NBIX
BenzingaOct 20, 2026, 12:31 PMBenzinga Newsdesk
Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease.
NBIX